면역요법용 의약품 시장 보고서(2026년)

Drugs for immunotherapy are medications designed to either stimulate or suppress the immune system to help the body defend itself against cancer, infections, and other diseases. Immunotherapy is a form of treatment that assists the immune system in recognizing and combating cancer, while also supporting the body's natural ability to fight infections and various disorders.

The primary types of drugs used in immunotherapy include monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and others. Monoclonal antibodies are produced by cloning a single white blood cell, with all resulting antibodies originating from one parent cell. These therapies are applied across areas such as cancer, autoimmune and inflammatory diseases, infectious diseases, and others, and are utilized in sectors including hospitals and clinics, ambulatory surgical centers, and others.

Tariffs have impacted the drugs for immunotherapy market by increasing costs for imported biologics, monoclonal antibodies, vaccines, and related reagents. Segments like monoclonal antibodies, checkpoint inhibitors, and therapeutic vaccines are most affected, with North America, Europe, and Asia-Pacific regions reliant on imports facing higher expenses and supply delays. However, tariffs have also encouraged domestic production, investment in local R&D, and development of cost-optimized immunotherapy solutions.

The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with a drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drugs for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drugs for immunotherapy market size has grown rapidly in recent years. It will grow from $310.48 billion in 2025 to $349.53 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to limited immunotherapy options, reliance on conventional cancer treatments, growing incidence of cancer and autoimmune diseases, increasing clinical trials for monoclonal antibodies, rising healthcare infrastructure.

The drugs for immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $570 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to development of bispecific and conjugated antibodies, expansion of personalized immunotherapy, increasing adoption of checkpoint inhibitors, rising investments in therapeutic vaccine research, integration of digital patient monitoring and AI-guided immunotherapy. Major trends in the forecast period include rising adoption of monoclonal antibodies and checkpoint inhibitors, growth in cancer immunotherapy and autoimmune disease treatments, increasing development of therapeutic and preventive vaccines, expansion of t-cell receptor and cytokine-based therapies, integration of immunotherapy in ambulatory and hospital-based care.

The rising level of healthcare expenditure is expected to drive the growth of the drugs for immunotherapy market in the coming years. Healthcare expenditure represents the total spending on healthcare products and services within a specific region or country over a given period, including costs related to physician consultations, hospitalizations, surgical procedures, diagnostic services, and medical treatments. Financial resources for healthcare are provided by individuals, healthcare providers, insurance organizations, and government bodies to support the cost of immunotherapy drugs and related treatments. For example, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering Medicare and Medicaid, healthcare spending in the United States increased by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. As a result, increasing healthcare expenditure is contributing to the expansion of the drugs for immunotherapy market.

Major companies operating in the drugs for immunotherapy market are concentrating on the development of innovative products, such as Keytruda (pembrolizumab), to deliver effective and reliable treatment options. Keytruda is an immunotherapy drug classified as an immune checkpoint inhibitor and is used as a targeted therapy for adult patients. For instance, in January 2023, Merck & Co., Inc., a US-based pharmaceutical company, launched Keytruda (pembrolizumab) following approval from the Food and Drug Administration. Keytruda is used to treat multiple types of cancer by activating the immune system to recognize and attack cancer cells and is approved as an adjuvant treatment for non-small cell lung cancer (NSCLC). This approval represents an important advancement in cancer therapy and is expected to positively influence the healthcare sector.

In December 2024, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer aims to strengthen its oncology portfolio by expanding into advanced immunotherapy approaches, particularly through Seagen's antibody-drug conjugate technologies for targeted cancer treatment. Seagen Inc. is a US-based biotechnology company specializing in the development and manufacturing of antibody-drug conjugates.

Major companies operating in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co. Inc., UbiVac, Bayer AG, Celgene Corporation, Incyte Corporation, Juno Therapeutics Inc., Bluebird bio, Celldex Therapeutics, BeiGene, BioNTech AG, CytomX Therapeutics, Eisai Co. Ltd., Flexus Biosciences Inc., Genscript Biotech Corporation, Harpoon Therapeutics Inc., Heptares Therapeutics Ltd., Ignyta Inc., Immatics Biotechnologies, Jounce Therapeutics Inc.

North America was the largest region in the immunotherapy market in 2025. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drugs for immunotherapy market consist of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drugs for Immunotherapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses drugs for immunotherapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drugs for immunotherapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drugs for immunotherapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Monoclonal Antibodies; Interferons; Interleukins; Vaccines; Checkpoint Inhibitors; Other Types
• 2) By Therapy Area: Cancer; Autoimmune & Inflammatory Diseases; Infectious Diseases; Other Therapy Areas
• 3) By End User: Hospitals & Clinics; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Monoclonal Antibodies: Naked Monoclonal Antibodies; Conjugated Monoclonal Antibodies; Bispecific Monoclonal Antibodies
• 2) By Interferons: Interferon Alfa; Interferon Beta; Interferon Gamma
• 3) By Interleukins: Interleukin-2 (IL-2); Interleukin-6 (IL-6); Interleukin-12 (IL-12)
• 4) By Vaccines: Preventive Vaccines; Therapeutic Vaccines
• 5) By Checkpoint Inhibitors: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4 Inhibitors
• 6) By Other Types: Cancer Cell Therapies; Cytokine Therapy; T-Cell Receptor Therapy
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Novartis AG; Merck & Co. Inc.; UbiVac; Bayer AG; Celgene Corporation; Incyte Corporation; Juno Therapeutics Inc.; Bluebird bio; Celldex Therapeutics; BeiGene; BioNTech AG; CytomX Therapeutics; Eisai Co. Ltd.; Flexus Biosciences Inc.; Genscript Biotech Corporation; Harpoon Therapeutics Inc.; Heptares Therapeutics Ltd.; Ignyta Inc.; Immatics Biotechnologies; Jounce Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Drugs for Immunotherapy Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Drugs for Immunotherapy Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Drugs for Immunotherapy Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Drugs for Immunotherapy Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Monoclonal Antibodies And Checkpoint Inhibitors
  • 4.2.2 Growth In Cancer Immunotherapy And Autoimmune Disease Treatments
  • 4.2.3 Increasing Development Of Therapeutic And Preventive Vaccines
  • 4.2.4 Expansion Of T-Cell Receptor And Cytokine-Based Therapies
  • 4.2.5 Integration Of Immunotherapy In Ambulatory And Hospital-Based Care

5. Drugs for Immunotherapy Market Analysis Of End Use Industries

• 5.1 Hospitals & Clinics
• 5.2 Ambulatory Surgical Centers
• 5.3 Oncology Centers
• 5.4 Research Laboratories
• 5.5 Pharmaceutical Companies

6. Drugs for Immunotherapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Drugs for Immunotherapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Drugs for Immunotherapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Drugs for Immunotherapy Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Drugs for Immunotherapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Drugs for Immunotherapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Drugs for Immunotherapy Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Drugs for Immunotherapy Market Segmentation

• 9.1. Global Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types
• 9.2. Global Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas
• 9.3. Global Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users
• 9.4. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
• 9.5. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Interferons, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Interferon Alfa, Interferon Beta, Interferon Gamma
• 9.6. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Interleukins, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Interleukin-2 (IL-2), Interleukin-6 (IL-6), Interleukin-12 (IL-12)
• 9.7. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Preventive Vaccines, Therapeutic Vaccines
• 9.8. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Checkpoint Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
• 9.9. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cancer Cell Therapies, Cytokine Therapy, T-Cell Receptor Therapy

10. Drugs for Immunotherapy Market Regional And Country Analysis

• 10.1. Global Drugs for Immunotherapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Drugs for Immunotherapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Drugs for Immunotherapy Market

• 11.1. Asia-Pacific Drugs for Immunotherapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Drugs for Immunotherapy Market

• 12.1. China Drugs for Immunotherapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Drugs for Immunotherapy Market

• 13.1. India Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Drugs for Immunotherapy Market

• 14.1. Japan Drugs for Immunotherapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Drugs for Immunotherapy Market

• 15.1. Australia Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Drugs for Immunotherapy Market

• 16.1. Indonesia Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Drugs for Immunotherapy Market

• 17.1. South Korea Drugs for Immunotherapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Drugs for Immunotherapy Market

• 18.1. Taiwan Drugs for Immunotherapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Drugs for Immunotherapy Market

• 19.1. South East Asia Drugs for Immunotherapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Drugs for Immunotherapy Market

• 20.1. Western Europe Drugs for Immunotherapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Drugs for Immunotherapy Market

• 21.1. UK Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Drugs for Immunotherapy Market

• 22.1. Germany Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Drugs for Immunotherapy Market

• 23.1. France Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Drugs for Immunotherapy Market

• 24.1. Italy Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Drugs for Immunotherapy Market

• 25.1. Spain Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Drugs for Immunotherapy Market

• 26.1. Eastern Europe Drugs for Immunotherapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Drugs for Immunotherapy Market

• 27.1. Russia Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Drugs for Immunotherapy Market

• 28.1. North America Drugs for Immunotherapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Drugs for Immunotherapy Market

• 29.1. USA Drugs for Immunotherapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Drugs for Immunotherapy Market

• 30.1. Canada Drugs for Immunotherapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Drugs for Immunotherapy Market

• 31.1. South America Drugs for Immunotherapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Drugs for Immunotherapy Market

• 32.1. Brazil Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Drugs for Immunotherapy Market

• 33.1. Middle East Drugs for Immunotherapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Drugs for Immunotherapy Market

• 34.1. Africa Drugs for Immunotherapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Drugs for Immunotherapy Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Drugs for Immunotherapy Market Regulatory and Investment Landscape

36. Drugs for Immunotherapy Market Competitive Landscape And Company Profiles

• 36.1. Drugs for Immunotherapy Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Drugs for Immunotherapy Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Drugs for Immunotherapy Market Company Profiles
  • 36.3.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. UbiVac Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

37. Drugs for Immunotherapy Market Other Major And Innovative Companies

• Celgene Corporation, Incyte Corporation, Juno Therapeutics Inc., Bluebird bio, Celldex Therapeutics, BeiGene, BioNTech AG, CytomX Therapeutics, Eisai Co. Ltd., Flexus Biosciences Inc., Genscript Biotech Corporation, Harpoon Therapeutics Inc., Heptares Therapeutics Ltd., Ignyta Inc., Immatics Biotechnologies

38. Global Drugs for Immunotherapy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Drugs for Immunotherapy Market

40. Drugs for Immunotherapy Market High Potential Countries, Segments and Strategies

• 40.1 Drugs for Immunotherapy Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Drugs for Immunotherapy Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Drugs for Immunotherapy Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer